CX3CR1 is a potential biomarker of immune microenvironment and prognosis in epithelial ovarian cancer

Danfeng Shao,Honger Zhou,Huaiying Yu,Xiaoqing Zhu
DOI: https://doi.org/10.1097/md.0000000000036891
IF: 1.6
2024-01-20
Medicine
Abstract:Ovarian cancer is the most lethal of all gynecological cancers worldwide. In the United States and China, >21,400 and 57,200 women been newly diagnosed with ovarian cancer. [ 1 , 2 ] Due to nonspecific symptoms and the ovary's location deep within the pelvic cavity, approximately 60% to 70% of ovarian cancer cases are diagnosed at advanced International Federation of Gynecology and Obstetrics stages (III and IV), resulting in delayed diagnoses and treatments. As a result, the 5-year survival rate for stage III and IV cases is 27% and 13%, respectively. [ 3 , 4 ] Ovarian cancer is a heterogeneous tumor with various histological types. Among them, epithelial ovarian cancer accounts for around 90% of all ovarian malignancies. [ 5 ] Currently, debulking surgery and chemotherapy containing platinum remain the standard treatment for epithelial ovarian cancer. [ 6 ]
medicine, general & internal
What problem does this paper attempt to address?